156 related articles for article (PubMed ID: 9351533)
1. Who should receive recombinant factor VIII?
Giangrande PL
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic products and difficult decisions. The case of recombinant factor VIII in the management of haemophilia A.
Green C; Akehurst R
J Public Health Med; 1998 Jun; 20(2):137-8. PubMed ID: 9675729
[TBL] [Abstract][Full Text] [Related]
3. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
4. Million dollar miracles.
Smith SD
Minn Med; 2006 Apr; 89(4):30-5, 51. PubMed ID: 16681280
[No Abstract] [Full Text] [Related]
5. UK: Hemophiliac wins access to recombinant factor VIII.
Gold J
Can HIV AIDS Policy Law Rev; 2003 Dec; 8(3):62. PubMed ID: 15108666
[TBL] [Abstract][Full Text] [Related]
6. Participation in research: the economic advantages in a haemophilia research population.
Wasserman J; Ullman M; Cantini M; Moynihan K; Hoots WK
Haemophilia; 2000 Sep; 6(5):571-4. PubMed ID: 11012704
[No Abstract] [Full Text] [Related]
7. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
8. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
[TBL] [Abstract][Full Text] [Related]
9. Previously untreated patients and recombinant factor VIII concentrate studies.
Pasi KJ
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party.
Hay CR; Colvin BT; Ludlam CA; Hill FG; Preston FE
Blood Coagul Fibrinolysis; 1996 Mar; 7(2):134-8. PubMed ID: 8735802
[TBL] [Abstract][Full Text] [Related]
11. Psychosocial issues surrounding the general or restricted use of recombinant factor VIII: hemophilia clinic perspective.
McDonald JR
Transfus Med Rev; 1992 Oct; 6(4):277-9. PubMed ID: 1421829
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A.
Hay JW; Ernst RL; Kessler CM
Haemophilia; 1999 May; 5(3):191-202. PubMed ID: 10444287
[TBL] [Abstract][Full Text] [Related]
13. Guidelines on treatment of haemophilia in Sweden.
Berntorp E
Haemophilia; 1998 Jul; 4(4):425-6. PubMed ID: 9873768
[No Abstract] [Full Text] [Related]
14. Treatment for haemophilia by postcode.
Ludlam CA; Hay CR; Dolan G
BMJ; 1997 Mar; 314(7082):749. PubMed ID: 9116559
[No Abstract] [Full Text] [Related]
15. Haemophiliac patient goes to High Court to get synthetic factor VIII.
Dyer C
BMJ; 2003 Nov; 327(7426):1250. PubMed ID: 14644957
[No Abstract] [Full Text] [Related]
16. UK Haemophilia Centre Doctors' Organisation guidance on the use of extended-half-life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treaters.
Hermans C; Van Damme A; Dolan G; Maes P; Peerlinck K
Haemophilia; 2018 Sep; 24(5):e378-e380. PubMed ID: 30182454
[No Abstract] [Full Text] [Related]
17. The use of recombinant factor VIII in the management of hemophilia.
Mannucci PM; Gringeri A
Ric Clin Lab; 1991; 21(1):1-7. PubMed ID: 1907760
[TBL] [Abstract][Full Text] [Related]
18. Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey.
Peyvandi F; Palla R; Franchi C; Nobili A; Rosendaal FR; Mannucci PM
Haemophilia; 2018 Jul; 24(4):e266-e268. PubMed ID: 29869363
[No Abstract] [Full Text] [Related]
19. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.
Teitel JM; Card R; Strawczynski H
Haemophilia; 1998 Sep; 4(5):731-8. PubMed ID: 9873879
[TBL] [Abstract][Full Text] [Related]
20. National haemophilia treatment protocols: Canada.
Teitel JM
Haemophilia; 1998 Jul; 4(4):422-3. PubMed ID: 9873766
[No Abstract] [Full Text] [Related]
[Next] [New Search]
